Yttriga

Yttriga (Yttrium-90) is a radiopharmaceutical used for targeted therapy in medical treatments. This radioactive isotope delivers localized radiation for therapeutic purposes. Suitable for intravenous administration under professional supervision.

Yttrium-90, found in Yttriga, is primarily used in radiopharmaceutical therapies to treat certain cancers. It delivers targeted radiation to cancer cells while minimizing exposure to healthy tissue. This approach is often used in conditions requiring localized radiation therapy.

As a radioactive isotope, Yttrium-90 emits beta radiation to destroy targeted cells. Its effects are localized to the treatment area, reducing systemic impact. Patients may experience temporary effects related to the treatment site during administration.

Yttriga must be handled and administered by trained healthcare professionals only. Proper shielding and safety protocols are required due to its radioactive nature. Patients should follow all medical guidance regarding preparation and post-treatment care.

Radiopharmaceuticals like Yttriga may interact with other medications or treatments affecting bone marrow or blood cell counts. Patients should disclose all current medications to their healthcare provider. Alcohol and certain supplements may also require caution during treatment.